19
September , 2017
Tuesday

Email This Post Email This Post

Daily medication reduces stroke risk and avoids side effects of transfusions; called “major advancement”


Dr. Russell Ware, MD PhD, director of Hematology at Cincinnati Children’s Hospital Medical Center, is one of the leading researchers of the study.

Nationwide (BlackNews.com) For young sickle cell anemia (SCA) patients at the highest risk of stroke, a daily dose of the medication hydroxyurea provides management of the disease that is just effective as monthly blood transfusions, without the issues of iron overload and antibody formation which are sources of morbidity in these children. That finding is the result of a recent clinical trial that was halted a year early by the National Heart, Lung, and Blood Institute (NHLBI) because its findings were so conclusive.

“Hydroxyurea clearly works as well as blood transfusions to lower the risk of a child with sickle cell anemia having a stroke. Only rarely is a study stopped early for success,” said Russell Ware, MD PhD, director of Hematology at Cincinnati Children’s Hospital Medical Center, which served as the study’s Medical Coordinating Center. “This is a major advancement.”

The trial was conducted at 25 medical centers in the U.S. and Canada, comparing the standard therapy of monthly blood transfusions with the alternative of taking a daily pill of hydroxyurea. It included children between the ages of four and 16 who were at the highest risk for stroke. 121 children took part in the trial, with about half receiving blood transfusions and half receiving hydroxyurea.

The positive results researchers observed in the study open the door to more treatment options for clinicians trying to prevent strokes in children living with SCA, according to Ware.

Over the past decade, the laboratory and clinical effectiveness of hydroxyurea has been demonstrated in children and adults with SCA. Originally developed as a drug to treat cancer and infections, hydroxyurea boosts fetal hemoglobin production in patients with SCA, preventing the red blood cells from acquiring the sickle shape that fuels the many complications.

Hydroxyurea has been previously shown to be effective for a variety of sickle-related complications, but this was the first trial that demonstrated its benefits for children at increased risk of stroke.

Barry R. Davis, MD, PhD, was principal investigator for the study’s Data Coordinating Center at the University of Texas Health Science Center at Houston (UTHealth) School of Public Health. Serving as co-principal investigator for the study’s neurological core was Robert J. Adams, MD, Medical University of South Carolina.

For more information, please visit:

Cincinnati Children’s Hospital Medical Center – www.cincinnatichildrens.org
University of Texas Health Science Center at Houston (UTHealth) – www.uth.edu
Medical University of South Carolina – http://academicdepartments.musc.edu/musc/


You can leave a response, or trackback from your own site.

Leave a Reply

You must be logged in to post a comment.

Recent Comments

Welcome to CopyLine Magazine! The first issue of CopyLine Magazine was published in November, 1990, by Editor & Publisher Juanita Bratcher. CopyLine’s main focus is on the political arena – to inform our readers and analyze many of the pressing issues of the day - controversial or otherwise. Our objectives are clear – to keep you abreast of political happenings and maneuvering in the political arena, by reporting and providing provocative commentaries on various issues. For more about CopyLine Magazine, CopyLine Blog, and CopyLine Television/Video, please visit juanitabratcher.com, copylinemagazine.com, and oneononetelevision.com. Bratcher has been a News/Reporter, Author, Publisher, and Journalist for 33 years. She is the author of six books, including “Harold: The Making of a Big City Mayor” (Harold Washington), Chicago’s first African-American mayor; and “Beyond the Boardroom: Empowering a New Generation of Leaders,” about John Herman Stroger, Jr., the first African-American elected President of the Cook County Board. Bratcher is also a Poet/Songwriter, with 17 records – produced by HillTop Records of Hollywood, California. Juanita Bratcher Publisher

Recent Posts